Haemonetics - HAE Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HAE shares.
View HAE analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12 month target prices for Haemonetics' shares. Their HAE share price forecasts range from $88.00 to $115.00. On average, they anticipate the company's stock price to reach $101.00 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for HAE or view top-rated stocks among Wall Street analysts.

Haemonetics' stock was trading at $78.65 at the beginning of 2023. Since then, HAE shares have decreased by 1.6% and is now trading at $77.42.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our HAE earnings forecast.

Haemonetics Co. (NYSE:HAE) issued its earnings results on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier had revenue of $305.30 million for the quarter, compared to analysts' expectations of $300.47 million. Haemonetics had a trailing twelve-month return on equity of 19.84% and a net margin of 8.48%. The firm's revenue for the quarter was up 17.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.84 EPS.

ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap Momentum ETF (XMMO), Harbor Health Care ETF (MEDI), Cultivar ETF (CVAR), First Trust Mid Cap Growth AlphaDEX Fund (FNY), First Trust Active Factor Mid Cap ETF (AFMC), Fidelity Small-Mid Cap Opportunities ETF (FSMO) and Vanguard S&P Mid-Cap 400 Growth ETF (IVOG).

Haemonetics issued an update on its FY 2023 earnings guidance on Tuesday, February, 7th. The company provided earnings per share guidance of $2.90-$3.00 for the period, compared to the consensus earnings per share estimate of $2.92. The company issued revenue guidance of $1.14 billion-$1.16 billion, compared to the consensus revenue estimate of $1.14 billion.

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Steelhead Partners LLC (9.91%), Neuberger Berman Group LLC (7.68%), Fisher Asset Management LLC (2.19%), Schroder Investment Management Group (1.89%), Geode Capital Management LLC (1.80%) and Dimensional Fund Advisors LP (1.45%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HAE stock can currently be purchased for approximately $77.42.

Haemonetics (NYSE:HAE) has a market capitalization of $3.91 billion and generates $993.20 million in revenue each year. The medical instruments supplier earns $43.38 million in net income (profit) each year or $1.85 on an earnings per share basis.

The company employs 2,821 workers across the globe.

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.